1 / 13

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence. Jill A. Morris, PA-S. Objectives/Goals . Review the current controversy regarding antidepressant use as treatment in child and adolescent patients with depression Review studies concerning:

monita
Télécharger la présentation

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S

  2. Objectives/Goals • Review the current controversy regarding antidepressant use as treatment in child and adolescent patients with depression • Review studies concerning: • The safety and efficacy of SSRIs in young patients • The risk of suicidal ideation associated with SSRIs in children and adolescent patients • Suicide attempts versus suicide deaths • Summary/Conclusions

  3. Depression

  4. Background:Depression in Children and Adolescents • Depression is one of the most common diagnosable mental disorders in children and adolescents • Suicide is one of the risk factors associated with depression • SSRIs have been the “Gold Standard” for treating depression in children and adolescents • The downfall: SSRIs now have a warning regarding suicidality in children and adolescents • There is limited evidence supporting the safety (with concerns of suicidality) and efficacy of these drugs • Based on the extrapolation of data from adult studies

  5. STUDY #1The Use of Antidepressants to Treat Depression in Children and Adolescents • Investigated the efficacy profiles of different antidepressants • Involved large RCT’s involving subjects 18 years old and younger with depression • Reviewed by the FDA: • 6 published reports • 3 of fluoxetine and 1 each of paroxetine, sertraline, and citalopram • 10 unpublished reports • 2 each of paroxetine, venlafaxine, nefazodone, and mirtazapine and 1 each of citalopram and escitalopram

  6. Efficacy Profiles of Different Antidepressants: Published Trials

  7. Efficacy Profiles of Different Antidepressants: Unpublished Trials

  8. STUDY #2Suicidality in Pediatric Patients Treated with Antidepressant Drugs • Investigated the relationship between antidepressant drugs and suicidality in pediatric patients in randomized placebo-controlled trials • Data was derived from 4582 patients in 24 trials • 16 trials studied patients with MDD with the remaining 8 studied OCD (n=4), generalized anxiety disorder (n=2), and ADHD (n=1) • Only 20 trials were included in the risk ration analysis of suicidality because 4 trials had no events in the drug or placebo groups

  9. Summary of the Overall Risk Ratio of the Primary Outcome by Drug Across all Indications and in MDD Trials

  10. STUDY #3Antidepressant drug therapy and suicide in severely depressed children and adults • Design: Case control study • Methods: Researchers used records to compare prescription histories between 263 children and teenagers (6-18 years) who had attempted suicide and 1241 controls who had never attempted suicide (all subjects suffered from depression) • Objective: To evaluate the risk of suicide death and serious suicide attempt in relation to antidepressant use

  11. Summary of Associations of Suicide Attempts and Completion with Antidepressant Treatment

  12. Summary • Warnings include all antidepressant medications • Increase in suicidal ideation and behavior are relatively common in depression whereas completed suicides are far less common • It is common that a slight increase in ideation does not in fact increase actual completed suicides • Use of antidepressant drugs in pediatric patients is associated with a modestly increased risk of suicidality • The average risk of suicide ideation/behavioral tendencies in patients receiving antidepressants was 4%, twice the placebo risk of 2%; No suicides occurred in these trials • Fluoxetine is the only SSRI approved by FDA for use in children and adolescents and is the most efficacious and safest • Real world data does not suggest completed suicide rate has increased with greater antidepressant use • Causal association between antidepressants and suicide has not been confirmed; further studies are still needed to confirm of safety and efficacy in children and adolescents

  13. References Cheung, Amy. The use of antidepressants to treat depression in children and adolescents. CMAJ. 2006; 174(2). Clinical Advisory and Issue Analysis Regarding Antidepressant Use in Children and Adolescents. New Your State Office of Mental Health. 2004. Hammad, Tarek A. Suicidality in Pediatric Patients Treated with Antidepressant Drugs. Archives of General Psychiatry. 2006; 63(3): 332-339. Olfson, Mark. Antidepressant Drug Therapy and Suicide in Severely Depressed Children and Adults. Archives of General Psychiatry. 2006; 63(8): 865-872. Rosack, Jim. Clinical Trials Controversy Spotlights Flawed System. American Psychiatric Association. 2004; 39(14): 1. Son, Sung E. Depression in Children and Adolescents. American Academy of Family Physicians. 2000; 62(10): 2297-2308, 2311-2. www.mhawinchester.org www.nmha.org www.wikipedia.org

More Related